Lutikizumab (ABT-981) met its primary end point and all 8 ranked secondary end points in the phase 3 INTREPID trial ...
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results